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Abstract (337 words/350 words): 24 
 25 
Background:  26 
Records of medication prescriptions can be used in conjunction with pharmacy dispensing 27 
records to investigate the incidence of adherence, which is defined as observing the treatment 28 
plans agreed between a patient and their clinician.   Using prescribing records alone fails to 29 
identify primary non-adherence; medications not being collected from the dispensary.  Using 30 
dispensing records alone means that cases of conditions that resolve and/or treatments that are 31 
discontinued will be unaccounted for.  While using a linked prescribing and dispensing dataset 32 
to measure medication non-adherence is optimal, this linkage is not routinely conducted.  33 
Furthermore, without a unique common event identifier, linkage between these two datasets is 34 
not straightforward.    35 
 36 
Methods:  37 
We undertook a secondary analysis of the Salford Lung Study dataset. A novel probabilistic 38 
record linkage methodology was developed matching asthma medication pharmacy dispensing 39 
records and primary care prescribing records, using semantic (meaning) and syntactic 40 
(structure) harmonization, domain knowledge integration, and natural language feature 41 
extraction.  Cox survival analysis was conducted to assess factors associated with the time to 42 
medication dispensing after the prescription was written.  Finally, we used a simplified record 43 
linkage algorithm in which only identical records were matched, for a naïve benchmarking to 44 
compare against the results of our proposed methodology. 45 
 46 
Results:  47 
 3 
We matched 83% of pharmacy dispensing records to primary care prescribing records.  Missing 48 
data were prevalent in the dispensing records which were not matched – approximately 60% 49 
for both medication strength and quantity.  A naïve benchmarking approach, requiring perfect 50 
matching, identified one-quarter as many matching prescribing records as our methodology.    51 
Factors associated with delay (or failure) to collect the prescribed medication from a pharmacy 52 
included season, quantity of medication prescribed, previous dispensing history and class of 53 
medication.   Our findings indicate that over 30% of prescriptions issued were not collected 54 
from a dispensary (primary non-adherence).  55 
 56 
Conclusions:  57 
We have developed a probabilistic record linkage methodology matching a large percentage of 58 
pharmacy dispensing records with primary care prescribing records for asthma medications. 59 
This will allow researchers to link datasets in order to more accurately extract information 60 








Medication data can be used in research to assess changes in medication prescribing trends 68 
over time (1), for pharmacovigilance studies, and to investigate patients not adhering to the 69 
treatment plans agreed upon with their General Practitioner (GP) (2–4).   Investigating 70 
medication data enables researchers to estimate the frequency, burden, and costs of non-71 
adherence (5–7), identify the most at-risk to suboptimal clinical outcomes, evaluate the 72 
effectiveness of adherence interventions (8–10), and appropriately adjust for the impact of non-73 
adherence on safety and efficacy data in clinical trials (11,12).   74 
 75 
In studies of linked (or integrated) prescribing and dispensing records, failure to collect the 76 
initial asthma prescription (primary non-adherence) has reported incidence between 12-45% 77 
(13–17), with high variance due to differences in the right censoring point.  Studies across 78 
multiple chronic conditions reported a pooled general primary non-adherence rate of 9-17% 79 
(18–20).   80 
 81 
In England, prescribing and dispensing of medications are recorded by separate processes.  82 
After a medication prescription is issued to a patient by a GP or another authorized prescriber 83 
(21), the prescription is taken to a dispensing outlet such as a community pharmacy (22).  When 84 
the prepared medicine is released to the patient, details relating to payment for medications are 85 
recorded and managed by the NHS Business Services Authority (NHSBSA).  While analysis 86 
of medication adherence can be estimated using either the GP’s prescribing records or the 87 
NHSBSA medication dispensing records alone, there are limitations to each approach.  Without 88 
linking the records together, it is not possible to ascertain whether a prescribed medication was 89 
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collected, or to rule out other reasons for irregularities in collection such as treatment 90 
conclusion or sanctioned treatment interruptions (1,23,24).   91 
 92 
Since 2015, NHSBSA dispensing data have included a patient identifier (NHS number) (25); 93 
this is, however, not routinely linked to primary care prescribing records held by Public Health 94 
England (PHE). The NHSBSA and PHE records also do not have a common unique prescribing 95 
event identifier. Therefore, even with a data sharing agreement in place, matching records (one-96 
to-one) using common identifiers (known as deterministic linkage) is currently impossible.  97 
 98 
Therefore, it is necessary to link records probabilistically; estimating the likelihood that two 99 
records will match given the data they contain.  Neither pharmacy nor primary care records are 100 
written with future linkage in mind, and as such they often require substantial pre-processing.  101 
The quality of the data linkage can be improved by integrating domain knowledge to identify 102 
non-matching but equivalent values, for example converting between units of dose strength.   103 
 104 
The distinction between what should be considered deterministic or probabilistic is often 105 
disputed, as even complex probabilistic linkage processes can be broken down into their rule-106 
based components and both linkage types can allow for imperfect (or fuzzy) matching on certain 107 
features (26), such as the dates of events in our case (which we would not expect to match all 108 
the time).  The nature of administrative data source linkage, such as with Electronic Health 109 
Records, necessitates the use of fuzzy matching to overcome such prevalent qualities as 110 
missing data, free-text values, non-standardised units, and generic medication substitutions 111 
(resulting in different medication names).  There are cases in which deterministic linkage will 112 
not only reduce the overall accuracy of the linkage, but may also introduce bias (27,28). 113 
 114 
 6 
Padmanabhan et al. have previously demonstrated the methodology used for linking UK health 115 
datasets when the unique patient identifier (NHS number) contained missing and erroneous 116 
values prohibiting deterministic linkage, including the creation of a ranking system for 117 





The linkage of prescribing and dispensing records can enable the extraction of information 123 
about adherence to prescribed medications, including the identification of uncollected 124 
medications.  In this study, we sought to develop a novel methodology linking primary care 125 
prescribing and dispensing records without a common identifier, using heuristics and features 126 
extracted from free-text fields.    127 
 128 
The GUILD (30) and RECORD (31) guidelines for data linkage reporting were applied where 129 
necessary information was not reported elsewhere (32–34)).    130 
 131 
Data Source: 132 
The Salford Lung Study (SLS) was a prospective, 12-month, open-label, parallel group, 133 
randomised controlled trial (RCT) conducted in 74 general practice clinics in Salford and South 134 
Manchester, UK (35).  A total of 4,233 participants with asthma were recruited in primary care 135 
settings by the healthcare professionals who provided their normal everyday care, and 136 
randomly allocated to either initiate a combination fluticasone furoate/vilanterol treatment or 137 
to continue their maintenance therapy (“usual care”). 138 
 139 
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Participants were at least 18 years old at the time of recruitment, with a clinical diagnosis of 140 
symptomatic asthma made by a GP and had to be taking regular maintenance inhaler therapy 141 
with Inhaled CorticoSteroids (ICS) either alone or in combination with a Long-Acting β2-142 
Agonist (LABA). The main exclusion criteria were a recent history of life-threatening asthma, 143 
a history of Chronic Obstructive Pulmonary Disease (COPD), or concomitant life-threatening 144 
disease (34,36). Many of the participants in the study cohort would have been excluded from 145 
conventional RCTs due to their multi-morbidities (33,36), which increased the 146 
representativeness of the study cohort to the target population.   147 
 148 
The trial was registered in the National Institute of Health’s database of clinical studies (32) 149 
(clinicaltrials.gov identifier NCT01706198).  The study was conducted in accordance with the 150 
standards dictated by the National Research Ethics Service Committee North West (reference 151 
12/NW/0455), as well as the International Conference on Harmonisation, Good Clinical 152 
Practice, all applicable data protection requirements and the ethical principles outlined in the 153 
Declaration of Helsinki 2013.   154 
 155 
Data Format: 156 
The dispensing data contained 225,235 records, for 4,197 unique participants, between 27th 157 
November 2012 and 9th December 2016.    The prescribing dataset contained 339,792 records 158 
for 4,233 unique participants between 22nd November 2012 and 17th January 2017, however 159 
records outside of the dispensing data period were excluded.  160 
 161 
Both datasets contained a (common) subject ID, free text drug description, date (prescription 162 
or dispensing, respectively), the dose strength, dose instructions, and a numeric quantity of 163 
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medication prescribed (e.g. “200 dose inhaler”).  Between the two datasets, there were 8,291 164 
unique (free text) drug descriptions.   165 
 166 
Inclusion and Exclusion Criteria: 167 
All unique drug descriptions, in either the prescribing or dispensing records, were searched for 168 
the presence of one or more of the keywords listed in Appendix A.  From here, the drug classes 169 
were assigned: Short-Acting β2-Agonist (SABA), Long-Acting Muscarinic receptor 170 
Antagonist (LAMA), LABA, theophylline, ICS, LeukoTriene Receptor Antagonist (LTRA), 171 
cromoglicate, steroid, or immuno-suppressant.  If only one candidate class was identified, the 172 
drug class was coded according to the drug class keyword.  A drug was coded as an ICS and 173 
LABA combination medication (ICS+LABA) if active ingredients of both ICS and LABA 174 
varieties were flagged, a SABA if a medicine containing both SABA and LAMA ingredients 175 
were flagged.  Medications that did not match any of the keywords in Appendix A were 176 
considered to be non-asthma medications and were removed.  A medication class keyword was 177 
generated, containing a composite of the active ingredients, to be used in the matching 178 
algorithm.   179 
 180 
Furthermore, drug descriptions were searched for any of the exclusion keywords and brand 181 
names listed in Appendix B, which signalled that a medication was being used for an indication 182 
other than asthma (such as nasal spray corticosteroids for rhinitis).   183 
 184 
Variable Recoding: 185 
Several free text variables were recoded using custom look-up tables, to allow semantically 186 
identical, but syntactically variant (such as “128mcg” vs “128 micrograms”, and other type 187 
abbreviations and variations) records to be aligned.  Of note, we modified the recorded 188 
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medication quantity to estimate the number of doses (puffs), rather than the number of units 189 
(inhalers).  This variable integrates domain knowledge of the number of doses per unit for each 190 
medication strength combination (high potency medications are often dispensed at lower 191 
volumes), calculated using the most common volumes in the data.  In order to avoid candidate 192 
links being ruled out as potential matches on the basis of our quantity variable modifications, 193 
we included a so called ‘alias’ quantity (27), to be considered if the ‘primary’ quantity values 194 
did not match.  The process is summarized in Appendix C.   195 
 196 
Identification of Duplicates: 197 
Duplicates of prescribing and dispensing records are common due to errors in data entry (37–198 
39). Duplicate records in the data would have a strong adverse effect on the matching 199 
algorithm, as it would be forced to incorrectly match distinct records in one set to duplicates in 200 
the other.  We identified duplicate records by searching for commonalities within the same 201 
person, date (dispensing or prescribing respectively), medication brand name, and medication 202 
(active ingredient) keyword, in addition to the following combinations of (modified) variables: 203 
• Matched on quantity and dose 204 
• Matched on dose, and the quantity was not matched due to data missingness   205 
• Matched on quantity, and the dose was not matched due to data missingness. 206 
 207 
Data Linkage:   208 
The datasets of prescribing and dispensing records were merged such that a record (a candidate 209 
link) was generated for each eligible (common patient identifier and medication class) pair of 210 
records for matching. We note that the medication class keyword, composed of the active 211 
ingredients identified, was used in the place of a brand name such that generic substitutions 212 
would be identified as appropriate candidates for matching records.  Pairs of records were 213 
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eligible if the suggested dispensing date occurred after the prescription was written, but no 214 
more than six months after the prescription was written, at which point the prescription became 215 
invalid.   216 
 217 
Probabilistic linkage, which aims to match records based on multiple non-unique features, 218 
utilizes weights to determine the strength of a link.  These weights are numerical values 219 
representing the similarity of two records, derived using domain knowledge about the 220 
prevalence of dissimilarities between features in true matches.   221 
 222 
In this linkage, a rule-based approach, based on a simplified posterior multivariate distribution 223 
of clerically reviewed data and previous literature, was used to weight candidate links for 224 
estimated likelihood of being a true match.  Candidate links could then be ranked, and those 225 
with a linkage weight (calculation detailed in Appendix D) less than 70% excluded 226 
(combinations of features by match status that resulted in inclusion are listed, along with their 227 
sum weights, in Appendix E).   228 
 229 
Generic substitution for brand named medications are common (when permitted by the 230 
prescriber, known as open generic prescribing) in asthma controller medications (15,40,41).  231 
As such, brand name was assigned a lower maximum feature weight (20%) than the dose 232 
strength (35%; which will vary only when one record has a missing value, or in the rare case 233 
that a generic substitution requires a slightly different dosage) and quantity (35%; varying 234 
when a quantity was both uncommon and missing, and was imputed with a more prevalent but 235 
incorrect value).   The final 10% weight corresponded to the time between the prescribing and 236 
dispensing events.   Prescriptions issued less than one month prior to the dispensing were 237 
awarded the additional 10% weight, in line with the findings by Williams et al. that 95% of 238 
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asthma prescriptions are filled within this time window (14), however a higher weight was not 239 
implemented due to the use of the time between weights in the final match selection process. 240 
That is, each set of dispensing records for each person-medication combination were looped 241 
through from the last to first through, as follows: 242 
1. Identified the candidate in which the dispensing record occurs most recently after the 243 
prescription was written (record with highest match weight chosen if two candidate 244 
links on the same day were identified); this is a match between records, 245 
2. Removed all other candidate links which contain the dispensing record or the 246 
prescribing records relating to this match, 247 
3. Progressed to the previous dispensing for this person-medication. 248 
This process, illustrated in Figure 1, is also described in more detail in Appendix F.   249 
 250 
[[Insert Figure 1 here]] 251 
 252 
The most recent prescribing record before the dispensing was prioritised over more distant 253 
records with a higher match weight, as we considered it more likely that prescription records 254 
for the same person within such a short time window were for the same medication, recorded 255 
differently, rather than a new treatment.   256 
 257 
Prescriptions that did not match any dispensing record were marked as unclaimed.  We also 258 
noted dispensing records that were not matched (implying no corresponding prescription event) 259 
to assess linkage quality.    260 
 261 
Statistical Analysis Plan 262 
 12 
As per the recommendations by Harron et al., the characteristics of the matched and unmatched 263 
records were compared in order to identify potential sources of bias (42).  Specifically, the 264 
missingness for each variable used in the matching was compared between matched and non-265 
matched records, factors associated with prescription collection were assessed (statistical 266 
methodology described below), and the sensitivity of the algorithm parameters was tested by 267 
altering certain thresholds and requirements and comparing the proportion of records that were 268 
matched.   269 
 270 
As well as estimating the incidence of primary non-adherence, we used our linked dataset to 271 
analyse factors effecting the collection of prescribed medications.   By comparing our results 272 
to others using integrated health records (those that are linked, or linkable, inherently) we are 273 
able to demonstrate the validity of our linked dataset to answer epidemiological questions about 274 
high-risk individuals.   275 
 276 
We used multivariate Cox survival analysis to assess the statistical relationship between the 277 
season of the prescription, the drug class of the prescription, the number of previously 278 
unclaimed prescriptions, and the strength and quantity of the medication prescribed, on the 279 
time between the prescription being written and dispensed. Survival analysis calculates the 280 
rates (hazard rates) of medications being collected at any specific time since the prescription 281 
was written.  Comparing the ratios (hazard ratios) between two levels of a factor (such as male 282 
and female) allowed us to assess the difference that this factor made when everything else (age, 283 
medication, etc.) remained constant.  Although a prescription could be dispensed up to six 284 
months after it was written, it is uncommon that their collection will be delayed for more than 285 
7 days (14,15).  Furthermore, a delay of beyond one month would likely result in a gap in 286 
medication availability and thus be considered poor adherence.  As such, we wanted to find a 287 
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threshold at which prescriptions could be recorded as ‘hitherto uncollected’, known as being 288 
right censored.  We set this threshold at the minimum number of weeks such that fewer than 289 
2% of subsequently collected prescriptions would be right censored. 290 
 291 
Naïve Benchmarking 292 
We compared our results to those produced from a simplified algorithm in which records were 293 
pseudo-deterministically matched, such that candidate links required perfect matching on 294 
medication name, dose, quantity, and dose directions, without any variable recoding or removal 295 
of duplicate records.  The date variable, however, still allowed flexible matching as 296 
medications can be dispensed up to six months following prescription. 297 
 298 
The same iterative linkage procedure was used in the algorithm detailed previously, without 299 
the inclusion of the linkage weights as a tiebreaker between candidate links on the same day.   300 
 301 
As the dose directions were long, free-text strings, written separately by both the prescribing 302 
and dispensing agents, we also repeated the benchmarking analysis, with imperfect matching 303 
on the dose directions permitted.   304 
 305 
Links identified by this process should not be considered the ground truth, or the gold   306 
standard, as the algorithm will default to match records which are more distanced 307 
chronologically but similar syntactically, rather than semantically similar and chronologically 308 
closer record matches which are more likely to be estimated by the full algorithm.  As such, 309 
the matches identified between approaches will not be directly compared.   310 
 311 
Reporting  312 
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This study has been reported in accordance with the GUILD and RECORD reporting 313 
guidelines (30,31).   314 
 315 
Results 316 
Data Cleaning 317 
Of the 8,291 unique drug descriptions, 928 (11%) were identified as relating to asthma 318 
medications (list of keywords used in string search provided in Appendix A).  Searching the 319 
drug descriptions for the set of exclusion keywords led to the removal of 71 (8%) further 320 
records (list and frequency of keywords in Appendix B).  Removing the excluded medications 321 
left 88,916 prescribing records and 64,471 dispensing records (Figure 2).  Finally, duplicates 322 
were removed (12,236 prescribing records and 406 dispensing records), leaving 76,680 323 
prescribing records (86%) and 64,065 dispensing records (99%). 324 
 325 
[[Insert Figure 2 here]] 326 
 327 
 328 
Matching  329 
The full join on the prescribing and dispensing records generated 265,442 candidate links for 330 
linkage weight assessment (Appendix D).  62,783 candidate links were removed (23.7%) as 331 
they did not fulfil the minimum linkage weight threshold, leaving 202,659 candidates to be 332 
sorted through the matching algorithm.  After the algorithm was applied, 53,289 candidate 333 
links were confirmed as matches: 69.5% of prescribing records (n=76,680), and 83.2% of 334 
dispensing records (n=64,065).   335 
 336 
As shown in Figure 1: Diagram representing the data linkage algorithm. 337 
Figure 2: Data Linkage Flow Diagram. 338 
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Figure 3, there was a substantial discrepancy between the time between the prescribing and 339 
dispensing for the candidate links and the matches, with 99% of matches having less than one 340 
month between prescribing and dispensing (compared to 33% of candidate links).  341 
 342 
[[Insert Figure 3 here]] 343 
 344 
The median percentage of prescriptions claimed by an individual was 79%, with an 345 
interquartile range of 50-92% (range 0-100%).   23% of individuals claimed fewer than 50% 346 
of their prescriptions.  347 
 348 
Quality Assurance 349 
We inspected 23,391 prescribing records (31%) and 10,776 dispensing records (17%) for 350 
which a match could not be made (including those with candidate links which were not matched 351 
by the matching algorithm).  In the non-matched prescriptions, 9% (n=2,109/23,391) had 352 
missing medication dosage, and <1% (n=87/23,391) had missing data on quantity (both 353 
missing in less than <0.1%).  In the non-matched dispensing records, however, it was 62% 354 
(n=6,639/10,776) and 58% (n=6,222/10,776), respectively (both missing in 55%).    355 
 356 
Survival Analysis 357 
31% of prescriptions (n=23,391) were labelled as unclaimed.  In claimed prescriptions 358 
(n=53,289), the median time between the prescription being written and the medication being 359 
dispensed was 1 day (upper-lower inter-quartiles = 0-3 days), and fewer than 5% of people 360 
took longer than 1 week to claim (0.9% longer than 30 days).    Considering uncollected 361 
prescriptions to be right-censored at 6-months, at which point the prescription expires, the 362 
median time to collection was 3 days (upper-lower inter-quartiles = 0-178 days; Figure 4).   363 
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 364 
[[Insert Figure 4 here]] 365 
 366 
The multivariate Cox survival analysis model included 76,584 prescription records – having 367 
removed 96 with missing quantity.  The prescriptions were claimed in 52,186 of these records, 368 
with less than 2% being collected beyond 3 weeks after the prescription was issued.  As such, 369 
21 days was set as our right censoring point.  We found a lower hazard of claiming medications 370 
in summer (June-August: 3% decrease, 95% CI = 1-6%) compared to spring (Table 1), 371 
indicating that they were claimed slower in summer than in spring.  There was no statistically 372 
significant difference in the claiming of medications between spring and winter or spring and 373 
autumn.  Higher quantities (by number of doses) of prescribed medications were associated 374 
with modest reduction in hazard of collecting the medication (p<0.001).  Finally, proportions 375 
of previous prescriptions that were unclaimed (categorized into tertiles) were a strong predictor 376 
– with medium vs low tertiles hazard ratio of 0.57, and high vs low of 0.20 (p<0.001).  Rescue 377 
medication (SABA and steroids) had the highest hazard rates (1.433 and 1.839, respectively).  378 
Of the controller medications, those associated with higher asthma severity (according to the 379 
British Thoracic Society (BTS) treatment steps (43)), such as LAMA and LTRA medicines, 380 
had higher hazards than lower severity treatments such as ICS and combination ICS+LABA 381 
medications.     382 
 383 
[[Insert Table 1 here]] 384 
 385 
Naïve Benchmarking 386 
There were 88,916 prescribing records and 64,471 dispensing records identified relating to an 387 
asthma medication (without the removal of duplicates). Of these, 584 (0.7% of prescribing 388 
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records and 0.9% of dispensing records) were pseudo-deterministically linked.  Even when 389 
imperfect matching on dose-directions was permitted, only 15.4% of prescribing records and 390 




We have developed a novel methodology matching prescribing and dispensing electronic 395 
health records and demonstrated this led to matching 70% of asthma prescribing and 83% of 396 
dispensing records. Fewer than 5% of prescriptions were eventually claimed after one week of 397 
the issuing of the prescription.  30% of prescriptions were labelled as uncollected.   398 
 399 
The key strength of this study is the variety of integrated mechanisms – incorporating domain 400 
knowledge relating to asthma medications (such as semantic harmonization from brand name 401 
to active ingredients) and rule-based natural language feature extraction and harmonization 402 
(such as converting a free-text dose to a numeric value with common units).   403 
 404 
Using a naïve benchmarking algorithm that required perfect matching between prescribing and 405 
dispensing records (except for the date variable; pseudo-deterministic linkage), we were able 406 
to demonstrate the superiority of our proposed methodology.  In this benchmark linkage, only 407 
15% of the prescribing records and 21% of dispensing records were matched, even when 408 
imperfect matching on free-text dose directions was permitted.  This was a result of 409 
syntactically variant (different formats and value units) but semantically matching data 410 
between the two sources of information.   411 
 412 
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We identified a set of records for dispensed medications (17%) for which no matching 413 
prescribing record was identified.  In the non-matched dispensing records, 62% had missing 414 
medication strength, and 58% had missing quantity.  In its current state, the algorithm will not 415 
match records with high amounts of missing data even if no other match is identified.   416 
 417 
In Appendix D, we see that 3% of matches had distinct and non-missing medication brand 418 
names.  This highlights that potentially brand substitutions occurring at the pharmacy need to 419 
be accounted for in the matching (44).  The variable with the biggest change in distribution 420 
between the candidate links and the final matches was whether the medication was dispensed 421 
within one month of prescribing – 33% of candidates and 99% of matches (see Figure 1: 422 
Diagram representing the data linkage algorithm. 423 
Figure 2: Data Linkage Flow Diagram. 424 
Figure 3).  In fact, we found that only 1% of prescriptions were claimed more than a month 425 
after the prescription was written.   426 
 427 
Our finding that 30% of prescriptions were labelled as uncollected, known as primary non-428 
adherence, was a substantially higher proportion than the 8-20% found in previous asthma 429 
studies in US administrative health data studies (13–15,41,45).    One might assume that 430 
subsidised prescriptions, as we have in England, would result in higher primary adherence 431 
rates, as a barrier to adherence has been removed.  On the contrary, a recent study in Canada, 432 
where prescriptions are subsidised and thus considerably more affordable than in the USA, 433 
found that the fill rate for new asthma prescriptions was only 69% in adults (16).  As such, 434 
future work must be conducted in order to find cost-effective interventions to reduce primary 435 
non-adherence in asthma.   436 
 437 
As there is no true linkage event identifier (person-prescription), it is not possible to compare 438 
our identified matches to some ground truth, a common limitation highlighted in the 439 
aforementioned linkage quality assessment guidelines by Harron et al. (42).  As the 440 
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benchmarking analysis allowed prescribing and dispensing date variables to differ, hence 441 
pseudo-deterministic, even this does not identify ‘perfect matches’ between records.  If the 442 
ground truth was known, it would be possible to compare directly the matches estimated from 443 
the benchmark and pseudo-deterministic analyses and evaluate how well our algorithm 444 
improves the matching quality.   While the ground truth may not be possible to determine in 445 
challenging real-world data, even with manual review, one could also perturb data in which the 446 
ground truth is known to closer approximate the real use case, and evaluate the algorithm’s 447 
accuracy.   448 
 449 
In lieu of this, we conducted quality assurance comparing features of the matched and 450 
unmatched records, as recommended by Harron et al.’s guidelines (42).  We observed that 451 
prescriptions (for which the status of being non-matched might imply either medication non-452 
initiation, or not being correctly matched using the proposed algorithm) had missed medication 453 
strength in fewer than 10% of records, and missing quantity in fewer than 1%.  In the non-454 
matched dispensing records (which should occur only in rare emergency prescriptions and 455 
indicate shortcomings in matching prescription and dispensing records), 62% had missing 456 
strength and 58% had missing quantity. This indicates that one of the biggest barriers to 457 
successful record linkage was poor medication dispensing record quality.   458 
 459 
The frequency of non-matched dispensing records was our best indicator as to the quality of 460 
our linkage, however we found that 95% of these records that were missing quantity (58%) 461 
were also missing dose-strength.  As such, reducing the weight threshold from 70% to 50%, 462 
would have had a substantial effect on the pool of candidate links allowed to be used in the 463 
matching algorithm.  With so much missing data, however, the veracity of these matches would 464 
be hard to ascertain.   465 
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 466 
The strong influence of data quality on the success of the linkage algorithm makes it difficult 467 
to benchmark our results against other record linkage algorithms or even treatment initiation 468 
studies in populations with linkage conducted routinely.  Comparisons to algorithms derived 469 
in other medication indications, such as in acute conditions such as tuberculosis, or in other 470 
chronic illnesses such as mental health conditions, are even harder.  Furthermore, not all 471 
countries have a unique patient identifier, resulting in the use of demographic data such as 472 
gender, year of birth, and postcode, to identify entries belonging to the same person (46).  473 
Regardless, we find other studies have reported similar levels of inconsistency between 474 
features in matched records, such as brand name, dose strength, and time between prescribing 475 
and dispensing (44,47).   We also observed the substantial increase in matches when variables 476 
were cleaned, and recoded, and our probabilistic methodology was used in the place of a simple 477 
pseudo-deterministic matching.   478 
 479 
As with all probabilistic matching approaches, and particularly in cases such as these with 480 
considerable number of missing entries and un-structured fields, it is possible that matches 481 
even with high assigned weights are incorrect.  Indeed, it is not likely that the matches 482 
established in the benchmarking analysis are of higher accuracy than those in the primary 483 
analysis, and they cannot be directly compared.  In future work, this algorithm should be tested 484 
in simulated data where the underlying ground truth is known for further validation, in order 485 
to better determine the accuracy of the linkage.  There is potential that the design of the study 486 
on which this secondary analysis was conducted (a pragmatic randomised controlled trial) may 487 
have influenced the linkage in some way.  Validating the proposed linkage algorithm in further 488 
additional randomised clinical trials would be needed to establish the generalizability of our 489 
findings.   490 
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 491 
In addition to testing in other datasets, in which the true links are known and can be compared 492 
to the estimated matches, further development of this study would be to test the sensitivity of 493 
the model to certain parameters such as the weights for each component, the degree of influence 494 
from the dates, and the minimum weight threshold. We remark that these intrinsic parameters 495 
can be seen as degrees of freedom that enable data modellers to explore different levels of 496 
certainty for record matching. At a higher level, these can be thought of as the equivalent free 497 
parameters which need to be explored and optimised for a given dataset: for example, in 498 
Support Vector Machines (SVM) one needs to optimise the penalty hyper-parameter (and 499 
depending on configuration additional hyper-parameters too).  Consideration must also be 500 
taken to determine the acceptable limits of the false negative and positive rates, and the relative 501 
importance of the two, in specific settings.  For example, in adherence studies, one might 502 
conservatively prefer to underestimate adherence than to overestimate it, and thus prioritise 503 
lowering the false positive rate.   504 
 505 
Additionally, accounting for how much medication supply an individual currently has, or when 506 
their most recent previous prescription was issued, would allow the date component of the 507 
algorithm to correspond more meaningfully to the patient’s history.   As previously discussed, 508 
matching may also be improved by the addition of an extension allowing candidate pairs for 509 
which one record had high amounts of missing data and no match was identified to be re-510 
considered.   511 
 512 
Conclusions 513 
The optimal dataset for measurement of medication non-adherence includes both prescribing 514 
records and dispensing records, such that prescriptions that are not collected from the 515 
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dispensing agent and resolved/discontinued treatment regimens are accounted for. These are 516 
however seldom available.  We therefore developed a novel methodology that matched 83% 517 
of pharmacy dispensing records to primary care prescribing records.  In the 17% of dispensing 518 
records for which a match could not be identified, missing information was prevalent; 519 
particularly regarding the strength of the medication, and the quantity dispensed.  A naïve 520 
benchmarking, requiring perfect matching, identified prescribing records for only 21% of the 521 
dispensing records.  Although further evaluation of the quality of the data linkage is required, 522 
our novel methodology enables preliminary assessment of whether patients are collecting their 523 
prescribed asthma medications and can improve clinicians’ understanding of patient adherence.    524 
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Table 1: Cox Proportional hazards model risk factors associated with time to collecting a 753 
prescribed medication.  754 






Season   
   Spring {reference}  
   Summer 0.967 (0.944 - 0.991) 0.008 * 
   Autumn 0.981 (0.958 – 1.005) 0.123 
   Winter 1.003 (0.979 – 1.028) 0.791 
Drug Class   
   SABA 1.433 (1.387 - 1.479) <0.001 * 
   LABA 0.938 (0.890 - 0.990) 0.019 * 
   ICS {reference}  
   ICS+LABA 1.067 (1.033 – 1.102) <0.001 * 
   Cromoglicate 0.778 (0.389 – 1.558) 0.479 
   Immuno-suppressants 1.244 (1.100 - 1.408) <0.001 * 
   LAMA  1.349 (1.161 - 1.567) <0.001 * 
   LTRA 1.350 (1.289 – 1.414) <0.001 * 
   Theophylline 1.040 (0.897 - 1.205) 0.604 




   Low tertile {reference}  
   Mid tertile 0.565 (0.553 – 0.577) <0.001 * 
   High tertile 0.198 (0.193 – 0.204) <0.001 * 
Quantity of doses prescribed 1.000 ** (1.000 – 1.000) <0.001 * 
Statistically significant variables (using a threshold of p=0.05) are denoted by a star (*). 755 
** Coefficient 0.9999 to four decimal places, and therefore lower than the reference value 756 
 757 
  758 
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Figure Legends: 759 
 760 
Figure 1: Diagram representing the data linkage algorithm. 761 
Figure 2: Data Linkage Flow Diagram. 762 
Figure 3: Distributions of linkage weight points per variable, for candidates and final matches. 763 
Figure 4: Kaplan-Meier of the time to collecting prescriptions, censored at three weeks.  764 
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APPENDIX A: String Search Keywords by Medication and Drug Class Keyword Categories.   765 
Drug Class Keyword Medication Keyword String Search Keywords 













SABA BAMBUTEROL "BAMBUTEROL", 
"BAMBEC"      





"ATIMOS"      






LABA TERBUTALINE "TERBUTALINE", 
"BRICANYL"     
LABA TIOTROPIUM "TIOTROPIUM", "SPIRIVA"     














THEOPHYLLINE THEOPHYLLINE "THEOPHYLLINE", 
"NEULIN", "SLO-
PHYLLIN", 
"UNIPHYLLIN"   
THEOPHYLLINE AMINOPHYLLINE "AMINOPHYLLINE", 
"PHYLLOCONTIN" 





ICS CICLESONIDE "CICLESONIDE", 
"ALVESCO" 




"SPIROMAX"   







ICS MOMETASONE "MOMETASONE", 
"TWISTHALER", 
"ASMANEX"     
LTRA MONTELUKAST "MONTELUKAST", 
"SINGULAIR"    
LTRA ZAFIRLUKAST "ZAFIRLUKAST", 
"ACCOLATE" 
LTRA ZILEUTON "ZILEUTON", "ZYFLO"   
CROMOGLICATE NEDOCROMIL "NEDOCROMIL", 
"TILADE"   
CROMOGLICATE CROMOGLICATE "CROMOGLICATE", 
"CROMOGLYCATE", 
"INTAL"   
STEROID OMALIZUMAB "OMALIZUMAB", 
"XOLAIR"     
STEROID PREDNISOLONE "PREDNISOLONE" 
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IMMUNO-SUPPRESSANT AZATHIOPRINE "AZATHIOPRINE", 
"IMURAN" 
String search keywords may appear under multiple medication and drug class keyword 766 
categories, if they contain more than one active ingredient, such as combination ICS LABA 767 
medications. 768 




  773 
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APPENDIX B: EXCLUSION KEYWORDS AND FREQUENCY 774 
 775 














GASTRO * 1 



















TOTAL EXCLUDED 71 (7.7%) 
* Excluding medications of drug class “steroid” or “theophylline” 776 
** Excluding medications of drug class “steroid”, “theophylline”, “tiotropium” or 777 





APPENDIX C: Variable Recoding 782 
 783 
Quantity Recoding: 784 
Quantities with values of over 28 were assumed to be the number of doses, rather than the 785 
number of units/inhalers.  The most common recorded number of dose quantity was imputed 786 
as the most commonly occurring number of doses per unit (as the most common number of 787 
units prescribed is one) for that medication class. If the quantity was recorded in doses, this 788 
was set as the primary dose quantity, with the second most commonly occurring dose quantity 789 
as the alias value.  If the quantity was recorded in units, the number of units multiplied by the 790 
most commonly occurring dose quantity was imputed as the primary value, and the second 791 
most likely as the alias.   792 
 793 
Dose Strength Recoding: 794 
All dose strengths were converted into upper case, spaces were removed, and the following 795 
string substitutions were made: 796 
• “MICROGRAMS” replaced with “MCG”, 797 
• “MICROGRAM” replaced with “MCG”, 798 
• “MICROG” replaced with “MCG”, 799 
• “UNITS” replaced with “U” 800 
Strings were then searched for the first pattern of "0.5", "500", "400", "320", "200", "184", 801 
"160", "125", "100", "92", "80", "50", "25", "20", "10", "5", "4", "2", or "1", followed by any 802 
of “MG”, “MCG” or “/”.  ICS+LABA medications often recorded as X/X dose, in which the 803 
larger number relates to the ICS and the lower to the LABA.  Some records listed the 804 
 40 
ICS+LABA combination medicines as ICS/LABA dose, and some as LABA/ICS dose; as 805 
such, the possible patterns were searched in order of size, rather than position in string. 806 
  807 
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APPENDIX D: LINKAGE WEIGHT CALCULATOR 808 








Both records had non-





One or both of the records 
had a missing brand name 
10 0% 0% 
Both records had non-
missing, and matching, brand 
names 




Both records had non-





One or both of the records 
had a missing dose strength 
10 18.1% 9.0% 
Both records had non-
missing, and matching, dose 
strengths 




Both records had non-
missing, and distinct, primary 




One or both of the records 
had a missing primary 
quantity value, indicating that 
no value was observed or 
could be imputed 
10 9.8% <0.1% 
Both records had non-
missing, and distinct, primary 
dose quantities, but the alias 
of one record matched to the 
primary of the other 
15 4.9% 1.5% 
Both records had non-
missing, and matching, 
primary dose quantities 
35 81.1% 98.5% 
Date 
difference 
Dispensing occurred more 
than one month after 





Dispensing occurred within 
one month of prescription 
10 32.8% 98.7% 
* If a generic medication was used, the brand name was listed as ‘generic’809 
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APPENDIX E: INCLUDED FEATURE WEIGHT COMBINATIONS 810 
WEIGHT BRAND NAME DOSE STRENGTH QUANTITY DATES 
100 Non-missing and matching Non-missing and matching Non-missing and matching Less than one-month delay 
90 
One or more missing 
Non-missing and matching Non-missing and matching 
Less than one-month delay 
Non-missing and matching More than one-month delay 
80 
Non-missing and distinct 
Non-missing and matching 
Non-missing and matching 
Less than one-month delay 
Non-missing and matching Primary/alias match 
One or more missing Non-missing and matching More than one-month delay 
75 Non-missing and matching 
One or more missing Non-missing and matching 
Less than one-month delay 
Non-missing and matching One or more missing 
70 
Non-missing and distinct 
Non-missing and matching 
Non-missing and matching 
More than one-month delay 
Non-missing and matching 
Primary/alias match 
One or more missing Less than one-month delay 
811 
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APPENDIX F: LINKAGE ALGORITHM DESCRIPTION 812 
 813 
The matching algorithm iteratively searches through dispensing records, finding the closest 814 
matching prescription record and subsequently removing it from future iterations, for each 815 
person and medication class keyword.  The medication class keyword is generated by 816 
identifying the key active ingredients in a medication that are common between both generic 817 
and brand name equivalents, using a domain-knowledge look-up table.   818 
 819 
Starting with the first dispensing record, all candidate prescription record links (linkage weight 820 
over the threshold and prescription date up to a maximum of six months prior to dispensing) 821 
are identified.  The most recently prescribed candidate link for the dispensing is selected as the 822 
most likely match, using highest linkage weights to break ties, and the non-selected candidate 823 
links for both the matched dispensing record and the matched prescription record are excluded 824 
from future iterations.  The process repeats until every dispensing record has been considered, 825 
although it is possible that no candidate links will be available for some dispensing records at 826 
later iterations if all initial prescription candidates have been successfully matched to other 827 
dispensing records.   828 
